Merck Patents. Merck shall have the sole right to control the preparation, filing, prosecution and maintenance of Merck Patents using patent counsel of Merck's choice, at Merck's expense.
Merck Patents. Merck shall, at Merck’s expense, file, prosecute and maintain Merck Patents subject to Article 9.5 (h) below. Notwithstanding the foregoing, Merck may elect not to file, prosecute and maintain Merck Patents in whole or part and, if so, shall notify Licensor in writing at least ninety (90) days before any deadline applicable to the filing, prosecution or maintenance of such Merck Patent, as the case may be, or any other date by which an action must be taken to establish or preserve such Merck Patent, and Threshold shall, at Threshold’s expense, have the right to file, prosecute and maintain in whole or in part Merck Patents under the name of Merck. In such event, Merck shall execute such documents and perform such acts at Threshold’s expense as may be reasonably necessary to allow Threshold to continue such prosecution or maintenance.
Merck Patents. Filing Filing No. Publication Publication No. Xxxxx Xxxxx No. Expiry Date [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] *** Confidential Treatment Requested Schedule 1.1.104 Nexium Trademark Word marks [ ...***...] • In each case, including any derivatives, translations, transliterations or stylized forms of any of the foregoing word marks Design marks [...***...] *** Confidential Treatment Requested [...***...] Color xxxx [...***...] *** Confidential Treatment Requested Schedule 1.1.117 Permitted Encumbrances None. Schedule 1.1.124 Pozen Patents Filing Filing No. Publication Publication No. Xxxxx Xxxxx No. Expiry Date [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] *** Confidential Treatment Requested Schedule 1.1.136 Purchased Patents Filing Filing No. Publication Publication No. Xxxxx Xxxxx No. Expiry Date [...***... ] [...***...] [...***...] [...***...] [...***...] [ ...***... ] [...***...] [...***...] [...***...] [...***...] *** Confidential Treatment Requested Schedule 1.1.158 Vimovo Litigation [...***...] Plaintiffs Defendants US District Court Case No. [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] *** Confidential ...
Merck Patents. (a) Merck and MACI shall be solely responsible for the prosecution and maintenance of the Merck Patents, and Merck and MACI may cease prosecution and maintenance of any or all of such Merck Patents at any time without obligation to OSI. Merck and MACI shall have the sole right (but not obligation) to bring and control, at their own expense, any infringement action against any person or entity infringing the Merck Patents, and any recovery realized as a result of such action shall belong to Merck and/or MACI.
Merck Patents. Merck shall have the first right to bring and control any action or proceeding with respect to infringement of any Merck Patent at its own expense and by counsel of its own choice. With respect to infringement of any Merck Patent that could reasonably be expected to have a [***].
Merck Patents. Merck shall own any Know-How constituting a Sole Invention developed by Merck or any of its Affiliates or a Third Party on behalf of Merck and shall have the right, but not the obligation, to file, prosecute and maintain Patent Rights covering or claiming any such Know-How (“Merck Patent”). Merck shall bear all costs and expenses of filing, prosecuting and maintaining Merck Patents and Licensor shall have no particular rights with respect thereto.
Merck Patents. Merck shall have the sole right and authority, but not the obligation, to enforce Merck Patents against any Third Party infringer; provided, that Licensor shall provide reasonable assistance to Merck with respect thereto, including providing access to relevant documents and other evidence and making its employees available, subject to Merck’s reimbursement of any Out-of-Pocket Expenses incurred on an on-going basis in providing such assistance.
Merck Patents. Company acknowledges and agrees that Merck has the first right to prosecute and maintain the Merck Patents under the Merck License Agreement. TESARO shall promptly provide to Company any information received from Merck relating to the prosecution and maintenance of the Merck Patents. TESARO shall consult with Company, to the extent practicable, and shall consider Company’s comments in good faith, prior to exercising its rights under Sections 8.01 or 8.02 of the Merck License Agreement. If TESARO exercises its right under Section 8.02 of the Merck License Agreement to prosecute and maintain a Merck Patent, such Merck Patent shall be deemed to be an Other TESARO Patent and TESARO shall have the right to prepare, file, prosecute and maintain such Patent as set forth in Section 9.3(c).
Merck Patents. Filing Filing No. Publication Publication No. Xxxxx Xxxxx No. Expiry Date 15 Oct 2003 10/531412 20 Apr 2006 2006-0000000X0 05 Jun 2007 7227024 29 Jan 2024 16 May 2007 11/749282 03 Jan 2008 2008-0000000X0 23 Mar 2010 7683178 29 Jan 2024 08 Jul 1994 08/313342 04 May 1999 5900424 04 May 2016 23 Jan 1995 08/376512 03 Feb 1998 5714504 03 Feb 2015 16 Oct 2000 09/690044 05 Apr 2005 6875872 27 May 2014 03 Jul 1995 08/492087 07 Sep 1999 5948789 03 Jul 2015 01 Apr 2002 10/113245 02 Jan 2003 2003-0004190 08 Jun 2004 6747155 25 May 2018 25 Sep 2003 10/672936 07 Apr 2005 2005-0075369A1 12 Aug 2008 7411070 25 May 2018 11 Sep 2007 11/853323 16 Oct 2008 2008-0255363A1 29 Jun 2010 7745466 13 Oct 2018 14 Feb 2002 10/076711 26 Dec 2002 2002-0198239 13 Jan 2004 6677455 18 Jun 2018 25 May 1998 09/077719 09 Apr 2002 6369085 25 May 2018 Schedule 1.1.104 Nexium Trademark Word marks • NEXIUM • NEXIUM CONTROL • NEXIUM OTC • NEXIAM • INEXIUM • NEKSIUM • THE PURPLE PILL • In each case, including any derivatives, translations, transliterations or stylized forms of any of the foregoing word marks Design marks • Black dots device (Nexium logo) • White dots device Color xxxx • Purple colored capsule with two gold rings as described below: The colors PURPLE and GOLD are claimed as a feature of the xxxx. The colors PURPLE and GOLD as applied to the surface of a pharmaceutical capsule. The capsule (as shown in the drawing below) is PURPLE with two side-by-side GOLD rings that encircle the top of the capsule. The outline of the capsule is in broken lines and is intended merely to show the position of the xxxx but is not part of the xxxx. The drawing is lined for the colors PURPLE and GOLD. Below are representational images of the purple colored capsule with two gold rings. The positioning of text on the capsule may differ from the images shown. Schedule 1.1.117 Permitted Encumbrances None. Schedule 1.1.124 Pozen Patents Filing Filing No. Publication Publication No. Xxxxx Xxxxx No. Expiry Date 23 Aug 2011 13/215855 15 Mar 2012 US-2012-0064156-A1 15 Oct 2013 8557285 31 May 2022 03 Oct 2013 14/045156* 31 May 2022 31 May 2002 10/158216 10 Apr 2003 20030069255 09 Aug 2005 6926907 28 Feb 2023 * If Pozen amends the claims of this application to be specifically directed to aspirin products it will not longer be part of the collaboration between AstraZeneca and Pozen and therefore would no longer be a Pozen Patent Schedule 1.1.136 Purchased Patents Filing Filing No. Publication Publication No. Xxxxx ...
Merck Patents
